{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:37:59Z","timestamp":1790869079790,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1111\/igc.0b013e31819bdc7e","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T13:20:11Z","timestamp":1291382411000},"page":"223-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"Maurie","family":"Markman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Berek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","article-title":"Intraperitoneal antineoplastic drug delivery: rationale and results","volume":"4","author":"Markman","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1040-8428(99)00017-7","article-title":"Intraperitoneal chemotherapy","volume":"31","author":"Markman","year":"1999","journal-title":"Crit Rev Oncol\/Hem."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0015","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/gyno.1993.1191","article-title":"Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study","volume":"50","author":"Markman","year":"1993","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0040","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1006\/gyno.1998.5206","article-title":"A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study","volume":"71","author":"Feun","year":"1998","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0045","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/gyno.1995.1025","article-title":"Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a phase II Gynecologic Oncology Group trial","volume":"56","author":"Braly","year":"1995","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0090-8258(92)90482-X","article-title":"Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant alpha-interferon","volume":"45","author":"Markman","year":"1992","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1006\/gyno.1999.5455","article-title":"Intraperitoneal >-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study","volume":"74","author":"Berek","year":"1999","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1006\/gyno.1999.5532","article-title":"Intraperitoneal interferon-> in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study","volume":"75","author":"Berek","year":"1999","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0065","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.1998.16.8.2620","article-title":"Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study","volume":"16","author":"Markman","year":"1998","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0070","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.1987.5.10.1607","article-title":"Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy","volume":"5","author":"Howell","year":"1987","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/gyno.1998.4940","article-title":"Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer","volume":"68","author":"Recio","year":"1998","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0080","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.1992.10.9.1479","article-title":"Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0085","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2002.20.3.694","article-title":"Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up","volume":"20","author":"Barakat","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0090","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1200\/JCO.1991.9.10.1801","article-title":"Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00273393","article-title":"Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group","volume":"18","author":"DeGregorio","year":"1986","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00262740","article-title":"Pharmacokinetics of carboplatin after intraperitoneal administration","volume":"21","author":"Elferink","year":"1988","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0105","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0090-8258(90)90131-4","article-title":"Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer","volume":"36","author":"Pfeiffer","year":"1990","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e31819bdc7e_bb0110","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.1990.8.8.1335","article-title":"Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy","volume":"8","author":"Speyer","year":"1990","journal-title":"J Clin Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e31819bdc7e","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24026720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24026720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1111\/IGC.0b013e31819bdc7e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:07:49Z","timestamp":1753232869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24026720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1048891X24026720"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e31819bdc7e","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e31819bdc7e","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}